vs
PHIBRO ANIMAL HEALTH CORP（PAHC）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
ROYAL GOLD INC的季度营收约是PHIBRO ANIMAL HEALTH CORP的1.0倍（$375.3M vs $373.9M），ROYAL GOLD INC净利率更高（24.9% vs 7.3%，领先17.6%），ROYAL GOLD INC同比增速更快（85.3% vs 20.9%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 19.2%）
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
PAHC vs RGLD — 直观对比
营收规模更大
RGLD
是对方的1.0倍
$373.9M
营收增速更快
RGLD
高出64.4%
20.9%
净利率更高
RGLD
高出17.6%
7.3%
两年增速更快
RGLD
近两年复合增速
19.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.9M | $375.3M |
| 净利润 | $27.5M | $93.6M |
| 毛利率 | 35.5% | 64.6% |
| 营业利润率 | 13.5% | 56.2% |
| 净利率 | 7.3% | 24.9% |
| 营收同比 | 20.9% | 85.3% |
| 净利润同比 | 762.1% | -12.8% |
| 每股收益（稀释后） | $0.67 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAHCRGLD
| Q4 25 | $373.9M | $375.3M | ||
| Q3 25 | $363.9M | $252.1M | ||
| Q2 25 | $378.7M | $209.6M | ||
| Q1 25 | $347.8M | $193.4M | ||
| Q4 24 | $309.3M | $202.6M | ||
| Q3 24 | $260.4M | $193.8M | ||
| Q2 24 | $273.2M | $174.1M | ||
| Q1 24 | $263.2M | $148.9M |
净利润PAHCRGLD
| Q4 25 | $27.5M | $93.6M | ||
| Q3 25 | $26.5M | $126.8M | ||
| Q2 25 | $17.2M | $132.3M | ||
| Q1 25 | $20.9M | $113.5M | ||
| Q4 24 | $3.2M | $107.4M | ||
| Q3 24 | $7.0M | $96.2M | ||
| Q2 24 | $752.0K | $81.2M | ||
| Q1 24 | $8.4M | $47.2M |
毛利率PAHCRGLD
| Q4 25 | 35.5% | 64.6% | ||
| Q3 25 | 32.9% | 73.6% | ||
| Q2 25 | 29.0% | 72.6% | ||
| Q1 25 | 30.1% | 69.4% | ||
| Q4 24 | 32.9% | 70.3% | ||
| Q3 24 | 32.1% | 66.6% | ||
| Q2 24 | 31.9% | 64.7% | ||
| Q1 24 | 30.2% | 58.4% |
营业利润率PAHCRGLD
| Q4 25 | 13.5% | 56.2% | ||
| Q3 25 | 14.1% | 64.4% | ||
| Q2 25 | 8.9% | 67.7% | ||
| Q1 25 | 9.6% | 63.6% | ||
| Q4 24 | 8.3% | 65.9% | ||
| Q3 24 | 6.8% | 61.3% | ||
| Q2 24 | 6.7% | 58.6% | ||
| Q1 24 | 7.6% | 50.7% |
净利率PAHCRGLD
| Q4 25 | 7.3% | 24.9% | ||
| Q3 25 | 7.3% | 50.3% | ||
| Q2 25 | 4.5% | 63.1% | ||
| Q1 25 | 6.0% | 58.7% | ||
| Q4 24 | 1.0% | 53.0% | ||
| Q3 24 | 2.7% | 49.7% | ||
| Q2 24 | 0.3% | 46.6% | ||
| Q1 24 | 3.2% | 31.7% |
每股收益（稀释后）PAHCRGLD
| Q4 25 | $0.67 | $1.04 | ||
| Q3 25 | $0.65 | $1.92 | ||
| Q2 25 | $0.43 | $2.01 | ||
| Q1 25 | $0.51 | $1.72 | ||
| Q4 24 | $0.08 | $1.63 | ||
| Q3 24 | $0.17 | $1.46 | ||
| Q2 24 | $0.02 | $1.23 | ||
| Q1 24 | $0.21 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.5M | $233.7M |
| 总债务越低越好 | $624.2M | — |
| 股东权益账面价值 | $332.4M | $7.2B |
| 总资产 | $1.4B | $9.5B |
| 负债/权益比越低杠杆越低 | 1.88× | — |
8季度趋势，按日历期对齐
现金及短期投资PAHCRGLD
| Q4 25 | $74.5M | $233.7M | ||
| Q3 25 | $85.3M | $172.8M | ||
| Q2 25 | $77.0M | $248.2M | ||
| Q1 25 | $70.4M | $240.8M | ||
| Q4 24 | $67.1M | $195.5M | ||
| Q3 24 | $89.8M | $127.9M | ||
| Q2 24 | $114.6M | $74.2M | ||
| Q1 24 | $98.7M | $137.9M |
总债务PAHCRGLD
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | $0 | ||
| Q2 24 | $312.1M | $50.0M | ||
| Q1 24 | — | — |
股东权益PAHCRGLD
| Q4 25 | $332.4M | $7.2B | ||
| Q3 25 | $311.7M | $3.4B | ||
| Q2 25 | $285.7M | $3.3B | ||
| Q1 25 | $266.0M | $3.2B | ||
| Q4 24 | $246.8M | $3.1B | ||
| Q3 24 | $258.5M | $3.0B | ||
| Q2 24 | $256.6M | $3.0B | ||
| Q1 24 | $270.1M | $2.9B |
总资产PAHCRGLD
| Q4 25 | $1.4B | $9.5B | ||
| Q3 25 | $1.4B | $4.5B | ||
| Q2 25 | $1.4B | $3.6B | ||
| Q1 25 | $1.3B | $3.5B | ||
| Q4 24 | $1.3B | $3.4B | ||
| Q3 24 | $966.3M | $3.3B | ||
| Q2 24 | $982.2M | $3.3B | ||
| Q1 24 | $979.0M | $3.3B |
负债/权益比PAHCRGLD
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | 0.00× | ||
| Q2 24 | 1.22× | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $8.3M | — |
| 自由现金流率自由现金流/营收 | 2.2% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | 0.70× | 2.58× |
| 过去12个月自由现金流最近4个季度 | $47.3M | — |
8季度趋势，按日历期对齐
经营现金流PAHCRGLD
| Q4 25 | $19.4M | $241.7M | ||
| Q3 25 | $9.3M | $174.0M | ||
| Q2 25 | $21.3M | $152.8M | ||
| Q1 25 | $43.2M | $136.4M | ||
| Q4 24 | $3.1M | $141.1M | ||
| Q3 24 | $12.6M | $136.7M | ||
| Q2 24 | $28.4M | $113.5M | ||
| Q1 24 | $11.4M | $138.3M |
自由现金流PAHCRGLD
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
自由现金流率PAHCRGLD
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
资本支出强度PAHCRGLD
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
现金转化率PAHCRGLD
| Q4 25 | 0.70× | 2.58× | ||
| Q3 25 | 0.35× | 1.37× | ||
| Q2 25 | 1.24× | 1.15× | ||
| Q1 25 | 2.07× | 1.20× | ||
| Q4 24 | 0.97× | 1.31× | ||
| Q3 24 | 1.81× | 1.42× | ||
| Q2 24 | 37.80× | 1.40× | ||
| Q1 24 | 1.36× | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
